The role of corticosteroids in the regulation of vascular tone

Cardiovascular Research

Volumn 41, Issue 1, 1999, Pages 55-64

  Ullian, Michael E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ARGIPRESSIN; CORTICOSTEROID; CORTICOSTEROID RECEPTOR; CORTICOSTERONE; CORTICOTROPIN; DEOXYCORTICOSTERONE; DEXAMETHASONE; ENDOTHELIN; HYDROCORTISONE; NORADRENALIN; THROMBOXANE DERIVATIVE; VASOCONSTRICTOR AGENT; ANGIOTENSIN II; GLUCOCORTICOID; MINERALOCORTICOID;

BLOOD VESSEL TONE; DRUG POTENTIATION; HUMAN; HYPERTROPHY; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ION TRANSPORT; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TOPICAL DRUG ADMINISTRATION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HYPERTENSION;

ADRENAL CORTEX HORMONES; ANGIOTENSIN II; ANIMALS; GLUCOCORTICOIDS; HUMANS; HYPERTENSION; MINERALOCORTICOIDS; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, ANGIOTENSIN; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

EID: 0032588261     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00230-2     Document Type: Review

References (115)

1. Langford HG, Snavely JR. Effect of DCA on development of renoprival hypertension. Am J Physiol 1959;196:449-450.
2. Fuller PJ. The steroid receptor superfamily: mechanisms of diversi-ty. FASEB J 1991;5:3092-3099.
3. Kwak SP, Patel PD, Thompson RC, Akil H, Watson SJ. 5″-heterogeneity of the mineralocorticoid receptor messenger ribonucleic acid: differential expression and regulation of splice variants within the rat hippocampus. Endocrinology 1993;133:2344-2350.
4. Patel PD, Sherman TG, Goldman DJ, Watson SJ. Molecular cloning of a MC (Type I) receptor complementary DNA from rat hippocampus. Mol Endocrinol 1989;3:1877-1885.
5. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human MR complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;237:268-274.
6. Zennaro MC, Keightley MC, Kotelevtsev Y, et al. Human mineralocorticoid receptor genomic structure and identification of expressed isoforms. J Biol Chem 1995;270:21016-21020.
7. Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985;318:635-641.
8. Kernel L, Ramsay C, Kanamarlapudi N, Travers T, Packer W Evidence for the presence in arterial walls of intracellular-molecular mechanism for action of mineralocorticoids. Clin Exp Hypertens 1982;A4:1561-1582.
9. Meyer WJ, Nichols NR. MC binding in cultured smooth muscle cells and fibroblasts from rat aorta. J Steroid Biochem 1981;14:1157-1168.
10. Scott BA, Lawrence B, Nguyen HH, Meyer WJ. Aldosterone and dexamethasone binding in human arterial smooth muscle cells. J Hypertens 1987;5:739-744.
11. Lombes M, Oblin ME, Gasc JM, et al. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid re-ceptor. Circ Res 1992;7:503-510.
12. Wehling M. Specific, nongenomic actions of steroid hormones. Annu Rev Physiol 1997;59:365-393.
13. Fritz I, Levine R. Action of adrenal cortical steroids and norepinephrine on vascular responses of stress in adrenalectomized rats. Am J Physiol 1951;165:456-465.
14. Ramey ER, Goldstein MS, Levine R. Action of norepinephrine and adrenal cortical steroids on blood pressure and work performance of adrenalectomized dogs. Am J Physiol 1951;165:450-456.
15. Kadowitz PJ, Yard AC. Influence of hydrocortisone on cardiovascular responses to epinephrine. Eur J Pharmacol 1971;13:281-286.
16. Yard AC, Kadowitz PJ. Studies on the mechanism of hydrocortisone potentiation of vasoconstrictor responses to epinephrine in the anesthetized animal. Eur J Pharmacol 1972;20:19.
17. Reis DJ. Potentiation of the vasoconstrictor action of topical norepinephrine on the human bulbar conjunctival vessels after topical application of certain adrenocortical hormones. J Clin Endocrinol Metab 1960;20:446-456.
18. Lepri G, Christiani R. The ability of certain adrenocortical hormones to potentiate the vasoconstrictor action of noradrenaline on the conjunctival vessels in the rabbit and in man. Br J Ophthalmol 1964;48:205-208.
19. Fowler NO, Chou DH. Potentiation of smooth muscle contraction by adrenal steroids. Circ Res 1961;9:153-156.
20. Kurland GS, Freedberg AS. The potentiating effect of ACTH and of cortisone on pressor response to intravenous infusion of L-norepinephrine. Proc Soc Exp Med Biol 1951;78:28-31.
21. Whitworth JA, Connell JMC, Lever AF, Fraser R. Pressor responsiveness in steroid-induced hypertension in man. Clin Exp Pharmacol Physiol 1986;13:353-358.
22. Pirpiris M, Sudhir K, Yeung S, Jennings G, Whitworth JA. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992;19:567-574.
23. Berecek KH, Bohr DF. Whole body vascular reactivity during the development of deoxycorticosterone acetate hypertension in the pig. Circ Res 1978;42:764-771.
24. Handa M, Kondo K, Suzuki H, Saruta T. Dexamethasone hypertension in rats: role of prostaglandins in pressor sensitivity to norepinephrine. Hypertension 1984;6:236-241.
25. Perry PA, Webb RC. Agonist-sensitive calcium stores in arteries from steroid hypertensive rats. Hypertension 1991;17:603-611.
26. Perry PA, Webb RC. Sensitivity and adrenoceptor affinity in the mesenteric artery of the deoxycorticosterone acetate hypertensive rat. Can J Physiol Pharmacol 1988;66:1095-1099.
27. 2+ efflux in arteries from deoxycorticosterone acetate hypertensive rats. Hypertension 1992;19:734-738.
28. Longhurst PA, Rice PJ, Taylor DA, Fleming WW Sensitivity of caudal arteries and the mesenteric vascular bed to norepinephrine in DOCA-salt hypertension. Hypertension 1988;12:133-142.
29. Monney M, Schlegel PA, Brunner HR. Influence of sodium diet and deoxycorticosterone on the response to norepinephrine, lysine-vasopressin and angiotensin II of isolated perfused rat mesenteric arteries. Clin Exp Hypertens 1983;A5:1735-1747.
30. Couture R, Regoli D. Vascular reactivity to angiotensin and noradrenaline in rats maintained on a sodium free diet or made hypertensive with desoxycorticosterone acetate and salt. Clin Exp Hypertens 1980;2:25-43.
31. Soltis EE, Field FP. Sodium pump activity and norepinephrine responsiveness in femoral arterial smooth muscle from DOCA-salt rats. Pharmacology 1987;34:104-110.
32. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme not receptor mediated. Science 1988;242:583-585.
33. Ullian ME, Walsh LG. Corticosterone metabolism and effects on angiotensin II receptors in vascular smooth muscle. Circ Res 1995;77:702-709.
34. Brem AS, Bina RB, King T, Morris DJ. 11βOH-Progesterone affects vascular glucocorticoid metabolism and contractile response. Hypertension 1997;30:449-454.
35. Funder JW, Pearce PT, Smith R, Caompbell J. Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 1989;125:2224-2226.
36. Walker BR, Yau JL, Brett LP, et al. 11β-Hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids. Endocrinology 1991;129:3305-3312.
37. Brem AS, Bina RB, King T, Morris DJ. Bidirectional activity of 11β-hydroxysteroid dehydrogenase in vascular smooth muscle cells. Steroids 1995;60:406-410.
38. Teelucksingh S, Mackie ADR, Burt D, et al. Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet 1990;335:1060-1063.
39. Walker BR, Connacher AA, Webb DJ, Edwards CRW Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man. Clin Sci 1992;83:171-178.
40. Walker BR, Sang KS, Williams BC, Edwards CRW Direct and indirect effects of carbenoxolone on responses to glucocorticoids and noradrenaline in rat aorta. J Hypertens 1994;12:33-39.
41. Souness GW, Morris DJ. 11α- and 11β-hydroxyprogesterone, potent inhibitors of 11β-hydroxysteroid dehydrogenase, possess hypertensinogenic activity in the rat. Hypertension 1996;27:421-425.
42. Takeda Y, Miyamori I, Iki K, et al. Endogenous renal 11β-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension. Hypertension 1996;27:197-201.
43. Sessa WC, Nasjletti A. Dexamethasone selectively attenuates prostanoid-induced vasoconstrictor responses in vitro. Circ Res 1990;66:383-388.
44. Bockman CS, Jeffries WB, Pettinger WA, Abel PW. Reduced contractile sensitivity and vasopressin receptor affinity in DOCA-salt hypertension. Am J Physiol 1992;262:H1752-H1758.
45. Miyahara H, Imayama S, Hori Y, Suzuki H. Cellular mechanisms of the steroid-induced vascular responses in the rabbit ear artery. Gen Pharmacol 1993;24:1155-1162.
46. Beilin LJ, Wade DN, Honour AJ, Cole TJ. Vascular hyper-reactivity with sodium loading and with desoxycorticosterone induced hypertension in the rat. Clin Sci 1970;39:793-810.
47. Murasawa S, Matsubara H, Kizima K, et al. Glucocorticoids regulate Via vasopressin receptor expression by increasing mRNA stability in vascular smooth muscle cells. Hypertension 1995;26:665-669.
48. Burrell LM, Phillips PA, Stephenson JM, et al. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension 1994;23:737-743.
49. Reif MS, Troutman SL, Schafer JA. Sodium transport by rat cortical collecting tubule. J Clin Invest 1986;77:1291-1298.
50. May CN, Bednarik JA. Regional hemodynamic and endocrine effects of aldosterone and cortisol in conscious sheep. Hypertension 1995;26:294-300.
51. White RM, Rivera CO, Davison CB. Differential contribution of endothelial function to vascular reactivity in conduit and resistance arteries from deoxycorticosterone-salt hypertensive rats. Hypertension 1996;27:1245-1253.
52. Besse JC, Bass AD. Potentiation by hydrocortisone of responses to catecholamines in vascular smooth muscle. J Pharmacol Exp Ther 1966;154:224-238.
53. Meggs LG, Stitzel R, Ben-Ari J, et al. Upregulation of the vascular alpha-1 receptor in malignant DOCA-salt hypertension. Clin Exp Hypertens Ther Prac 1988;A10:229-247.
54. Eid H, DeChamplain J. Increased inositol monophosphate production in cardiovascular tissues of DOCA-salt hypertensive rats. Hypertension 1988;12:122-128.
55. Haigh RM, Jones CT. Effect of glucocorticoid on α1-adrenergic receptor binding in rat vascular smooth muscle. J Mol Endocrinol 1990;5:41-48.
56. Smith JM, Jones SB, Bylund DB, Jones AW Characterization of the alpha-1 adrenergic receptors in the thoracic aorta of control and aldosterone hypertensive rats: correlation of radioligand binding with potassium efflux and contraction. J Pharmacol Exp Ther 1987;241:882-890.
57. Sakaue M, Hoffman BB. Glucocorticoids induce transcription and expression of the α1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest 1991;88:385-389.
58. Schiffrin EL, Thome FS, Genest J. Vascular angiotensin II receptors in renal and DOCA-salt hypertensive rats. Hypertension 1983;5:V16-V21.
59. Schiffrin EL, Gutkowska J, Genest J. Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am J Physiol 1984;246:H608-H614.
60. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol 1985;63:1522-1527.
61. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angioten-sin II receptor binding and inositol phosphate responses. Hypertension 1992;20:67-73.
62. Ullian ME, Fine JJ. Mechanisms of enhanced angiotensin II-stimulated signal transduction in VSM by aldosterone. J Cell Physiol 1994;161:201-208.
63. Ullian ME, Walsh LG, Morinelli TA. Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res 1996;32:266-273.
64. Sato A, Suzuki H, Iwaita Y, et al. Potentiation of inositol trisphosphate production by dexamethasone. Hypertension 1992;19:109-115.
65. Schelling JR, DeLuca DJ, Koniexzkowski M, et al. Glucocorticoid uncoupling of angiotensin II-dependent phospholipase C activation in rat vascular smooth muscle cells. Kidney Int 1994;46:675-682.
66. Sato A, Suzuki H, Murakami M, et al. Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 1994;23:25-30.
67. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991;351:233-236.
68. Uno S, Guo DF, Nakajima M, et al. Glucocorticoid induction of rat angiotensin II type 1A receptor gene promoter. Biochem Biophys Res Commun 1994;204:210-215.
69. Nguyen PV, Parent A, Deng LY, et al. Endothelin vascular receptors and responses in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1992;19:II98-II104.
70. Fluckiger JP, Nguyen PV, Li G, Yang XP, Schiffrin EL. Calcium, phosphoinositide, and 1,2-diacylglycerol responses of blood vessels of deoxycorticosterone acetate-salt hypertensive rats to endothelin1. Hypertension 1992;19:743-748.
71. Schiffrin EL, Lariviere R, Li JS, Sventek P, Touyz RM. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 1995;25:769-773.
72. Hasegawa H, Nasjletti A, Rice K, Masson GM. Role of pituitary and adrenals in the regulation of plasma angiotensinogen. Am J Physiol 1973;225:1-6.
73. Chan JSD, Ming M, Nie ZR, et al. Hormonal regulation of expression of the angiotensinogen gene in cultured opossum kidney proximal tubular cells. J Am Soc Nephrol 1992;15:1516-1522.
74. Kalinyak JE, Perlman AJ. Tissue-specific regulation of angiotensinogen mRNA accumulation by dexamethasone. J Biol Chem 1987;262:460-464.
75. Ben-Ari ET, Lynch KR, Garrison JC. Glucocorticoids induce the accumulation of novel angiotensinogen gene transcripts. J Biol Chem 1989;264:13074-13079.
76. Mendelsohn FAO, Lloyd CJ, Kachel C, Funder JW. Induction of glucocorticoids of angiotensin converting enzyme production from bovine endothelial cells in culture and rat lung in vivo. J Clin Invest 1982;70:684-692.
77. Sim MK, Chan CS. Effect of experimentally-induced hypertension on angiotensin converting enzyme activity in the aortic endothelium and smooth muscle cum adventitia of the Sprague-Dawley rat. Life Sci 1992;50:1821-1825.
78. Fishel RS, Eisenberg S, Shai SY, et al. Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle. Hypertension 1995;25:343-349.
79. Lockette W, Otsuka Y, Carretero OA. The loss of endothelium-dependent vascular relaxation in hypertension. Hypertension 1986;8:II-61-II-66.
80. King CM, Webb RC. The endothelium partially obscures enhanced microvessel reactivity in DOCA hypertensive rats. Hypertension 1988;12:420-427.
81. Nolly H, Carretero OA, Lama MC, Miatello R, Scicli AG. Vascular kallikrein in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994;23:I185-I188.
82. Haigh RM, Jones CT, Milligan G. Glucocorticoids regulate the amount of G proteins in rat aorta. J Mol Endocrinol 1990;5:185-189.
83. Turla MB, Webb RC. Vascular responsiveness to protein kinase C activators in mineralocorticoid-hypertensive rats. J Hypertens 1991;9:209-215.
84. Calderone A, Oster L, Moreau P, et al. Altered protein kinase C regulation of phosphoinositide-coupled receptors in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994;23:722-728.
85. Kanse SM, Takahaski K, Warren JB, Ghatei M, Blood SR. Glucocorticoids induce endothelin release from vascular smooth muscle cells but not endothelial cells. Eur J Pharmacol 1991;199:99-101.
86. Ikeda U, Kanbe T, Nakayama I, et al. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β. Eur J Pharmacol 1995;290:69-73.
87. Niwa M, Tsutsumishita Y, Kawai Y, et al. Suppression of inducible nitric oxide synthase mRNA expression by tryptoquinone A. Biochem Biophys Res Commun 1996;224:579-585.
88. Wileman SM, Mann GE, Baydoun AR. Induction of L-arginine transport and nitric oxide synthase in vascular smooth muscle cells: synergistic actions of pro-inflammatory cytokines and bacterial lipopolysaccharide. Br J Pharmacol 1995;116:3243-3250.
89. + current in arterial smooth muscle cells from aldosterone-salt hypertensive rats. Am J Physiol 1995;269:H1246-H1257.
90. 3H]dihydropyridine binding in A7r5 vascular smooth muscle cells. Am J Physiol 1991;261:C106-C114.
91. 2+ in flux in vascular smooth muscle in vivo. Endocrinol Res 1995;21:203-210.
92. Jones AW, Hart RG. Altered ion transport in aortic smooth muscle during deoxycorticosterone acetate hypertension in the rat. Circ Res 1975;37:333-341.
93. Kornel L, Nelson WA, Manisundaram B, Chigurupati R, Hayashi T. Mechanism of the effects of glucocorticoids and mineralocorticoids on vascular smooth muscle contractility. Steroids 1993;58:580-587.
94. + channels. Steroids 1995;60:114-119.
95. Oguchi A, Ikeda U, Kanbe T, et al. Regulation of Na-K-ATPase gene expression by aldosterone in vascular smooth muscle cells. Am J Physiol 1993;265:H1167-H1172.
96. +-ATPase gene expression by corticosteroids in vascular smooth muscle cells. Am J Physiol 1996;270:C731-C739.
97. Stern N, Palant C, Ozaki L, Tuck ML. Dexamethasone enhances active cation transport in cultured aortic smooth muscle cells. Am J Hypertens 1994;7:146-150.
98. Davis JPL, Chipperfield AR, Harper AA. Accumulation of intracellular chloride by Na-K-Cl co-transport in rat arterial smooth muscle is enhanced in deoxycorticosterone acetate/salt hypertension. J Mol Cell Cardiol 1993;25:233-237.
99. - co-transport. Clin Sci 1991;81:73-78.
100. 22Na efflux from arterial smooth muscle. Hypertension 1984;6:425-430.
101. Christ M, Douwes K, Eisen C, et al. Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells. Hypertension 1995;25:117-123.
102. Christ M, Meyer C, Sippel K, Wehling M. Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol, and protein kinase C. Biochem Biophys Res Commun 1995;213:123-129.
103. Wehling M, Neylon CB, Fullerton M, Bobik A, Funder JW Nongenomic effects of aldosterone on intracellular Ca in vascular smooth muscle cells. Circ Res 1995;76:973-979.
104. Deng LY, Schiffrein EL. Effects of endothelin on resistance arteries of DOCA-salt hypertensive rats. Am J Physiol 1992;262:H1782-H1787.
105. Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994;24:183-188.
106. + exchange and growth in cultured vascular smooth muscle cells. J Cell Physiol 1988;137:391-401.
107. Longenecker JP, Kilty LA, Johnson LK. Glucocorticoid influence on growth of vascular wall cells in culture. J Cell Physiol 1982;113:197-202.
108. Longenecker JP, Kilty LA, Johnson LK. Glucocorticoid inhibition of vascular smooth muscle cell proliferation: influence of homologous extracellular matrix and serum mitogens. J Cell Biol 1984;98:534-540.
109. Villa AE, Guzman LA, Chen W, et al. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest 1994;93:1243-1249.
110. Ullian ME, Hutchison FN, Hazen-Martin DJ, Morinelli TA. Angiotensin II-aldosterone interactions on protein synthesis in vascular smooth muscle cells. Am J Physiol 1993;264:C1525-C1531.
111. Takeda Y, Miyamori I, Yoneda T, et al. Production of aldosterone in isolated rat blood vessels. Hypertension 1995;25:170-173.
112. Hatakeyama H, Miyamori I, Fujita T, et al. Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994;269:24316-24320.
113. Baker JB, Barsh GS, Carney DH, Cunningham DD. Dexamethasone modulates binding and action of epidermal growth factor in serum-free cell culture. Proc Natl Acad Sci USA 1978;73:1882-1886.
114. Yagil Y, Krakoff LR. The differential effect of aldosterone and dexamethasone on pressor responses in adrenalectomized rats. Hypertension 1988;11:174-178.
115. Provencher PH, Saltis J, Funder JW. Glucocorticoids but not mineralocorticoids modulate endothelin-1 and angiotensin II binding in SHR vascular smooth muscle cells. J Steroid Biochem Mol Biol 1995;52:219-225.